Piperacillin-tazobactam: Difference between revisions
From IDWiki
(Created page with "== Background == === Clinical Breakpoints === {| class="wikitable" ! rowspan="2" |Species ! rowspan="2" |ECV (μg/mL) ! colspan="4" |Breakpoints (μg/mL) ! colspan="4" |Break...") |
(No difference)
|
Revision as of 10:52, 10 September 2020
Background
Clinical Breakpoints
| Species | ECV (μg/mL) | Breakpoints (μg/mL) | Breakpoints (mm) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| S | I | SDD | R | S | I | SDD | R | ||
| Enterobacterales | ≤16/4 | 32/4-64/4 | — | ≥128/4 | ≥21 | 18-20 | — | ≤17 | |
| Pseudomonas aeruginosa | ≤16/4 | 32/4-64/4 | — | ≥128/4 | ≥21 | 15-20 | — | ≤14 | |
| Acinetobacter species | ≤16/4 | 32/4-64/4 | — | ≥128/4 | ≥21 | 18-20 | — | ≤17 | |
| Other non-Enterobacterales | ≤16/4 | 32/4-64/4 | — | ≥128/4 | |||||
| Anaerobes | ≤16/4 | 32/4-64/4 | — | ≥128/4 | |||||
| Haemophilus influenzae and Haemophilus parainfluenzae | ≤1/4 | — | — | ≥2/4 | ≥21 | — | — | — | |
| Gram-positive bacteria | susceptibility predicted by penicillin | ||||||||
